Boardroom Alpha
Start trial
10-Q primary document
BBOT · Quarterly Report (Form 10-Q) · Filed November 12, 2025

Bridgebio Oncology Therapeutics Inc — 10-Q exhibit

bbot-ex10_3.htm
Bridgebio Oncology Therapeutics Inc on Boardroom Alpha
EX-10.3

 

 

Exhibit 10.3

 

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

AMENDMENT NO. 2

 

TO TRANSITION SERVICES AGREEMENT

 

This Amendment No. 2 (“Amendment No. 2”) to the Agreement (as defined below) is made effective as of October 1, 2024 (the “Effective Date”) by and between BridgeBio Services, Inc., a Delaware corporation (“BBIO”) and TheRas, Inc., a Delaware corporation (“BBOT”). BBIO and BBOT may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement (as defined below) to the extent defined therein.

WHEREAS, BBIO and BBOT entered into that certain Transition Services Agreement, dated April 30, 2024 (the “Agreement”); and

WHEREAS, the Parties now wish to amend the Agreement to update the Service Schedule on Exhibit A thereto and to update the BBOT Services on Exhibit B thereto.

NOW, THEREFORE, in consideration of the covenants, conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.
Amendments.
1.1
Amendment to Service Schedule. Exhibit A of the Agreement is deleted in its entirety and replaced with the following new Exhibit A attached hereto.
1.2
Amendment to BBOT Services. Exhibit B of the Agreement is deleted in its entirety and replaced with the following new Exhibit B attached hereto.

Miscellaneous. This Amendment No. 2 together with the Agreement constitute the entire agreement of the Parties with respect to the matters set forth in this Amendment No. 2 and there are no other agreements, commitments or understandings among the Parties with respect to the matters set forth herein. All terms and conditions of the Agreement not expressly amended herein shall remain in full force and effect. The terms and conditions of this Amendment No. 2 shall prevail over any conflicting terms and conditions in the Agreement with regard to the subject matter herein. This Amendment No. 2 shall be construed and enforced in accordance with the laws of California.

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, each Party hereto has executed this Agreement as of the date first above written.

BridgeBio Services, Inc.

By: /s/ Neil Kumar

Name: Neil Kumar

Title: CEO

TheRas, Inc.

By: /s/ Eli Wallace

Name: Eli Wallace

Title: CEO

 

2

 

 

Exhibit A

Form of Service Schedule

Services as of October 1, 2024

[***]

3

 

 

Exhibit B

Individual Milestone Payments

[***]

BBOT Services

[***]

4

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer